Coalescing the power of Artificial Intelligence, Medicinal Chemistry and Biology

Read More Contact Us

About AIBResearch

We are a fast-growing, science-led, research and development company. The foundation of AIBR is to transform the future of healthcare by unlocking the power of science to prevent and cure cancer through pioneering interdisciplinary research, translating new knowledge into better prevention and treatment towards improved patients care. Our platform enables our collaborators to discover high-quality, novel molecules more rapidly, at lower cost with a higher likelihood of success. We harnessing our inhouse algorithms for the discovery of novel small molecule and peptide theraputics against client targets. We are proud of our drug discovery program to be leading this digital revolution by constantly developing an intensive discovery and validation pipelines for potent targeted leads.

News & Events

AIBResearch has grown to its initial manpower by 2x

Jan 2024

The research at AIBResearch has grown unprecedentedly. The research team has grown twice to its initial strength since establishment in 2023. The company has added two new international collaborators. Soon the company will expand its core leadership...

Keytruda and Merck jointly bagged another FDA approval against NSCLC

January 26, 2023 – FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer. The Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a &...

Dostarlimab-gxly for primary advanced or recurrent Endometrial cancer

July 31, 2023 - The Food and Drug Administration approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent endometrial cancer (EC) that is mismatch repair deficient (dMMR), a...